Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
15.48 HKD 0.00% Intraday chart for Hansoh Pharmaceutical Group Company Limited +3.61% -1.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nomura Downgrades Hansoh Pharmaceutical to Neutral From Buy, Adjusts Price Target to HK$15.03 From HK$13.01 MT
Hansoh Pharmaceutical Gets Nod to Trial Nephropathy Treatment Capsules MT
Hansoh Pharmaceutical Buys Back 3 Million Shares MT
Fed, China Property Outlooks Roil Asian Stock Markets MT
Hansoh Secures Chinese Nod For Clinical Trial Of Anti-Diabetes Drug MT
China Outlook, Tech Rally Roils Asian Stock Markets MT
Hansoh Pharmaceutical Units Gets Clinical Trial Notice in China for Schizophrenia Treatment MT
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets CI
Federal Reserve Outlook Mutes Asian Stock Markets MT
Hansoh Pharmaceutical’s Trustee Buys Back Shares MT
GSK plc Enters Exclusive License Agreement with Hansoh for HS-20093 CI
GSK Enters Exclusive License Agreement With Hansoh for HS-20093 Cancer Antibody DJ
Hansoh Pharmaceutical Grants GSK Subsidiary Marketing License for Tumor Drug HS-20093 MT
Games Workshop seals Amazon deal for Warhammer 40,000 AN
GSK looks for deals in China as rebuilds relationship AN
Hansoh Pharma's Three Drugs Added to China’s National Reimbursement Drug List MT
China OKs Clinical Trial for Hansoh Pharmaceutical Units' Hypertrophic Cardiomyopathy Treatment MT
Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice CI
China Grants Drug Registration Approval for Hansoh Pharma Unit's Skin Infection Treatment MT
Hansoh Pharmaceutical Grants GSK Subsidiary International Marketing License for HS-20089 MT
Hansoh Pharmaceutical Gets Nod to Test HS-20106 Injections MT
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections CI
Rising Interest Rates Blunt Asian Stock Markets MT
Hansoh Pharmaceutical Units Obtain Clinical Trial Approval for Solid Tumor Drug MT
Chart Hansoh Pharmaceutical Group Company Limited
More charts
Hansoh Pharmaceutical Group Company Limited specializes in the development, manufacture and marketing of pharmaceutical products for the treatment of tumor, infectious, metabolic and autoimmune diseases. Net sales break down by revenue source as follows: - sales of pharmaceutical products (99.1%); - sales of research and development services (0.9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
14.29 CNY
Average target price
16.33 CNY
Spread / Average Target
+14.21%
Consensus

Quarterly revenue - Rate of surprise